Loading...
Market
How many additional investments in radiopharmaceuticals will Eli Lilly make by the end of 2025?
3
Resolution / Starting Odds
No further investments • 25%
One additional acquisition or partnership • 25%
Two additional acquisitions or partnerships • 25%
Three or more additional acquisitions or partnerships • 25%
Financial statements, press releases
Story
Aktis Oncology and Eli Lilly Announce $1.1 Billion Strategic Collaboration
May 21, 2024, 01:10 PM
Aktis Oncology announced on Tuesday a strategic collaboration with Eli Lilly to develop novel anticancer radiopharmaceuticals. The partnership includes milestone payments of up to $1.1 billion and royalties on sales. Aktis will receive an upfront payment of $60 million. This collaboration follows Eli Lilly's acquisition of radiopharma company Point Biopharma for $1.4 billion last year, highlighting Lilly's deepening investment in radiopharmaceuticals.
View original story
Similar markets
Below $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Above $2 billion • 25%
1-2 acquisitions • 33%
3-5 acquisitions • 33%
More than 5 acquisitions • 34%
Less than $1 billion • 33%
$1-2 billion • 33%
More than $2 billion • 33%
Less than 5 • 25%
5 to 9 • 25%
10 to 14 • 25%
15 or more • 25%
None • 33%
1-2 new partnerships • 33%
More than 2 new partnerships • 33%
Yes • 50%
No • 50%
0 partnerships • 25%
1-2 partnerships • 25%
3-5 partnerships • 25%
More than 5 partnerships • 25%
None • 25%
1-2 partnerships • 25%
3-4 partnerships • 25%
More than 4 • 25%
1-2 diseases • 33%
3-4 diseases • 33%
5 or more diseases • 33%